IFCT-2402 LAG-MAPS A non-comparative phase IIR trial assessing fianlimab plus cemiplimab plus pemetrexed-platinum chemotherapy or cemiplimab plus pemetrexed-platinum chemotherapy for treatment-naive Pleural Mesothelioma (PM) patients

2024-519208-29-00 · tracked via the Priya Life Science EU tracker

Sponsor

Intergroupe Francophone De Cancerologie Thoracique

Sponsor type

Patient organisation/association

Therapeutic area

Neoplasms

Decision date

06/11/2025

Enrollment target

126

Sites

France

Condition studied

Pleural mesothelioma

Investigational medicinal product(s)

FianlimabLIBTAYO 350 mg concentrate for solution for infusion.

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Disease Control Rate (DCR) at 6 months, according to RECIST1.1 criteria modified for mesothelioma, as assessed by an Independent Review Committee (IRC)

Endpoint detail

Incidence, nature, and severity of adverse events (AE), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), Rate of Hyper-Progressive Disease (HPD), Progression Free Survival (PFS) as assessed by an IRC, PFS as assessed by the investigator, PFS according to the histological subtype epithelioid vs. non-epithelioid, Overall Survival (OS), Best Overall Response Rate (ORR), Clinically significant changes in symptoms and function, using EQ-5D-5L and LCSS-meso scores

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-519208-29-00 on CTIS ↗ ← All trials in the EU